Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study
Aim: Percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) commonly leads to dissections which are associated with higher target lesion revascularization (TLR) rates. Clinical and economic consequences of dissection management in the femoropopliteal artery following PTA,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2024-12-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846120470087204864 |
|---|---|
| author | Jan B Pietzsch Benjamin P Geisler Abigail M Garner Anne M Ryschon William A Gray Masahiko Fujihara Peter A Schneider |
| author_facet | Jan B Pietzsch Benjamin P Geisler Abigail M Garner Anne M Ryschon William A Gray Masahiko Fujihara Peter A Schneider |
| author_sort | Jan B Pietzsch |
| collection | DOAJ |
| description | Aim: Percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) commonly leads
to dissections which are associated with higher target lesion revascularization (TLR) rates. Clinical and
economic consequences of dissection management in the femoropopliteal artery following PTA, and
specifically the potential economic benefit of focal dissection repair using the novel Tack Endovascular
System, remain unknown. Methods: A decision-analytic model was used to estimate 24-month clinical
events, costs and quality-adjusted life year (QALY) gain for a Tack-supported versus status-quo PTA
strategy. Patient and lesion characteristics and TLR rates were derived from the PTA cohort of the TOBA II
clinical trial, an observational cohort, and literature. Cost–effectiveness was determined from a US payer
and provider perspective separately for the non-severe (grade A or B), severe (grade C and higher) and
the entire dissection cohort. Results: TLR rates were lower for the Tack-supported strategy compared with
PTA (7.7 vs 27.4% in the non-severe, 13.9 vs 25.8% in the severe and 12.0 vs 26.3% in the entire dissection
cohort). Cost and QALY differences were +$297/ + 0.0110 in the non-severe dissection cohort and -
$1602/ + 0.0067 in the severe dissection cohort, resulting in an incremental cost–effectiveness ratio (ICER)
of $25,622 in the non-severe cohort and dominance in the severe cohort and the entire cohort. Conclusion:
Compared with a ‘status-quo’ approach, proactive focal stenting may lead to fewer reinterventions and
improved quality of life. There appears to be a graded economic benefit of focal dissection treatment,
being cost-effective in non-severe dissections and even cost saving in severe dissections. |
| format | Article |
| id | doaj-art-31cab84838b84a60bd17d433dd3b49c1 |
| institution | Kabale University |
| issn | 2042-6313 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-31cab84838b84a60bd17d433dd3b49c12024-12-16T09:23:23ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132024-12-0114110.57264/cer-2024-0055Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II StudyJan B Pietzsch0https://orcid.org/0000-0002-5078-1939Benjamin P Geisler1Abigail M Garner2Anne M Ryschon3William A Gray4Masahiko Fujihara5Peter A Schneider6Wing Tech Inc., Menlo Park, CA USAInstitute of Social Medicine, Epidemiology & Health Economics, Charite – Universita¨ tsmedizin Berlin, corporate member of Freie Universitat Berlin & Humboldt Universitat zu Berlin, Berlin, Germany; Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA USAWing Tech Inc., Menlo Park, CA USAWing Tech Inc., Menlo Park, CA USALankenau Heart Institute, Wynnewood, PA USADepartment of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada, Japan; Department of Medicine & Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDivision of Vascular & Endovascular Surgery, University of California San Francisco, San Francisco, CA USAAim: Percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) commonly leads to dissections which are associated with higher target lesion revascularization (TLR) rates. Clinical and economic consequences of dissection management in the femoropopliteal artery following PTA, and specifically the potential economic benefit of focal dissection repair using the novel Tack Endovascular System, remain unknown. Methods: A decision-analytic model was used to estimate 24-month clinical events, costs and quality-adjusted life year (QALY) gain for a Tack-supported versus status-quo PTA strategy. Patient and lesion characteristics and TLR rates were derived from the PTA cohort of the TOBA II clinical trial, an observational cohort, and literature. Cost–effectiveness was determined from a US payer and provider perspective separately for the non-severe (grade A or B), severe (grade C and higher) and the entire dissection cohort. Results: TLR rates were lower for the Tack-supported strategy compared with PTA (7.7 vs 27.4% in the non-severe, 13.9 vs 25.8% in the severe and 12.0 vs 26.3% in the entire dissection cohort). Cost and QALY differences were +$297/ + 0.0110 in the non-severe dissection cohort and - $1602/ + 0.0067 in the severe dissection cohort, resulting in an incremental cost–effectiveness ratio (ICER) of $25,622 in the non-severe cohort and dominance in the severe cohort and the entire cohort. Conclusion: Compared with a ‘status-quo’ approach, proactive focal stenting may lead to fewer reinterventions and improved quality of life. There appears to be a graded economic benefit of focal dissection treatment, being cost-effective in non-severe dissections and even cost saving in severe dissections.adverse effectsangioplastyballooncosts and cost analysisdissectionperipheral arterial disease |
| spellingShingle | Jan B Pietzsch Benjamin P Geisler Abigail M Garner Anne M Ryschon William A Gray Masahiko Fujihara Peter A Schneider Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study Journal of Comparative Effectiveness Research adverse effects angioplasty balloon costs and cost analysis dissection peripheral arterial disease |
| title | Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study |
| title_full | Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study |
| title_fullStr | Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study |
| title_full_unstemmed | Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study |
| title_short | Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study |
| title_sort | clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery an exploratory analysis based on the toba ii study |
| topic | adverse effects angioplasty balloon costs and cost analysis dissection peripheral arterial disease |
| work_keys_str_mv | AT janbpietzsch clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT benjaminpgeisler clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT abigailmgarner clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT annemryschon clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT williamagray clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT masahikofujihara clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy AT peteraschneider clinicalandeconomicimplicationsoffocaldissectiontreatmentfollowingpercutaneoustransluminalangioplastyofthesuperficialfemoralarteryanexploratoryanalysisbasedonthetobaiistudy |